SABS - SAB Biotherapeutics says mid-stage trial for influenza therapy met main goal

SAB Biotherapeutics (NASDAQ:SABS) announced that its Phase 2a challenge study for experimental seasonal influenza therapy SAB-176 met the primary endpoint with statistical significance. However, the shares have lost ~2.5% in the pre-market. In the placebo-controlled study initiated in June 2021, 60 healthy adults were challenged with a pandemic influenza virus strain (pH1N1) and were treated with either SAB-176 (25 mg/kg dose) or a placebo. Having taken the nasopharyngeal swabs eight days after the inoculation, the primary endpoint of the trial (p = 0.026, one-sided) was reached as there was a significant decline in pH1N1 influenza viral load in those treated with SAB-176. The trial had also met the secondary endpoint with a reduction of flu signs and symptoms at Day 4 (p = 0.013, one-sided) in symptomatic patients. Further analyses of secondary endpoint data are in progress. The experimental therapy has demonstrated a favorable safety profile, with a majority of adverse events

For further details see:

SAB Biotherapeutics says mid-stage trial for influenza therapy met main goal